Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.59 |
| ▸ | BCL2 | P10415 | 1/20 | 0.59 |
| ▸ | BID | P55957 | 1/20 | 0.59 |
| ▸ | NOD2 | Q9HC29 | 4/20 | 0.56 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.56 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.56 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.56 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.56 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.56 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.56 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.56 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31599460 | 1.00 | CCR2 (0.72) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| Hydrochloric Acid SCHEMBL4119324 | 0.98 | CCR2 (0.71) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL6864420 | 0.90 | ALDH1A1 (0.73) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL16794402 | 0.90 | NOD1 (0.71) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL13802522 | 0.90 | CCR2 (0.76) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL3836440 | 0.88 | ALDH1A1 (0.62) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL3056166 | 0.88 | ALDH1A1 (0.62) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL6955317 | 0.87 | CCR2 (0.73) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL3146260 | 0.86 | CCR2 (0.64) | CCR2ALDH1A1LMNAMAPTMCL1 | |
| SCHEMBL13114468 | 0.86 | CCR2 (0.64) | CCR2ALDH1A1LMNAMAPTMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004108671-A1 | SUBSTITUTED INDOLES WITH SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-12-16 | — | — | WO | claimed |
| CN-104822267-B | The inhibitor and its application method that hepatitis b virus covalence closed cyclic DNA is formed | 巴鲁克·S·布伦博格研究所 | 2018-01-23 | — | — | CN | disclosed |
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| US-9657013-B2 | Inhibitors of hepatitis B virus covalently closed circular DNA formation and their method of use | BARUCH S. BLUMBERG INSTITUTE (US) | 2017-05-23 | — | — | US | disclosed |
| CN-104822267-A | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | BARUCH S BLUMBERG INST | 2015-08-05 | — | — | CN | disclosed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-02-05 | — | — | US | disclosed |
| EP-2819671-A2 | BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | Baruch S. Blumberg Institute (US) | 2015-01-07 | — | — | EP | disclosed |
| WO-2013130703-A2 | BINHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | INSTITUTE FOR HEPATITIS AND VIRUS RESEARCH (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | AVENTIS PHARMA S.A. (FR) | 2009-10-08 | — | — | US | disclosed |
| EP-1534695-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2008-06-11 | — | — | EP | disclosed |
| EP-1534268-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2006-11-02 | — | — | EP | disclosed |
| EP-1534268-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| EP-1534695-A2 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004108671-A1 | SUBSTITUTED INDOLES WITH SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LIMITED (IN) | 2004-12-16 | — | — | WO | disclosed |
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-12-02 | — | — | US | disclosed |
| WO-2004014851-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014300-A2 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242559-A1 | Novel indole derivatives, preparation thereof as medicinal products and pharmaceutical compositions, and especially as KDR inhibitors | FLT4, KDR, CYP3A4 | CCR2 318/4885ALDH1A1 1515/4885LMNA 4771/4885 |
| US-20090253697-A1 | Novel Indole Derivatives, Preparation Thereof as Medicinal Products and Pharmaceutical Compositions, and Especially as KDR Inhibitors | KDR, FLT1, FLT4 | CCR2 1242/4885ALDH1A1 326/4885LMNA 3126/4885 |
| US-20150038515-A1 | INHIBITORS OF HEPATITIS B VIRUS CONVALENTLY CLOSED CIRCULAR DNA FORMATION AND THEIR METHOD OF USE | HAVCR2, PCNA, DNMT1 | CCR2 2192/4885ALDH1A1 4030/4885LMNA 418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.